

K1199 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP10964b**Specification**

K1199 Antibody (C-term) Blocking peptide - Product InformationPrimary Accession [Q8WUJ3](#)**K1199 Antibody (C-term) Blocking peptide - Additional Information****Gene ID** 57214**Other Names**

Cell migration-inducing and hyaluronan-binding protein, CEMIP, KIAA1199

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

K1199 Antibody (C-term) Blocking peptide - Protein Information**Name** CEMIP ([HGNC:29213](#))**Function**

Mediates depolymerization of hyaluronic acid (HA) via the cell membrane-associated clathrin-coated pit endocytic pathway. Binds to hyaluronic acid. Hydrolyzes high molecular weight hyaluronic acid to produce an intermediate-sized product, a process that may occur through rapid vesicle endocytosis and recycling without intracytoplasmic accumulation or digestion in lysosomes. Involved in hyaluronan catabolism in the dermis of the skin and arthritic synovium. Positively regulates epithelial-mesenchymal transition (EMT), and hence tumor cell growth, invasion and cancer dissemination. In collaboration with HSPA5/BIP, promotes cancer cell migration in a calcium and PKC- dependent manner. May be involved in hearing.

Cellular Location

Nucleus. Cytoplasm. Endoplasmic reticulum. Cell membrane. Membrane, clathrin-coated pit. Secreted. Note=Retained in the endoplasmic reticulum (ER) in a HSPA5/BIP-dependent manner. Colocalized with clathrin heavy chain/CLTC in clathrin-coated vesicles. Strongly detected in the cytoplasm of breast carcinoma cells, whereas poorly detected in adjacent normal epithelial cells, stromal cells, or benign breast tissues. Localized in the nucleus and cytoplasm of colon adenocarcinomas

Tissue Location

Expressed in dermal and in synovial fibroblasts. Strongly expressed in gastric cancers compared with the paired normal tissues. Strongly expressed in both ductal carcinoma and invasive breast cancer cells compared with benign epithelial cells (at protein level). Strongly expressed in brain, placenta, prostate, breast, lung and testis. Expressed in fibroblasts, epithelial cells and cancer cells. In ear, it is specifically expressed in inner ear. Expressed in cochlea and vestibule tissues. Strongly expressed in gastric cancers compared with the paired normal tissues. Strongly expressed in colon adenocarcinomas compared with normal colonic mucosas. Strongly expressed in breast cancer as compared to normal breast tissue

K1199 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

K1199 Antibody (C-term) Blocking peptide - Images

K1199 Antibody (C-term) Blocking peptide - Background

May be involved in hearing.

K1199 Antibody (C-term) Blocking peptide - References

Rose, J. Phd, et al. Mol. Med. (2010) In press :Matsuzaki, S., et al. Ann. Surg. Oncol. 16(7):2042-2051(2009)Michishita, E., et al. Cancer Lett. 239(1):71-77(2006)Guo, J., et al. FEBS Lett. 580(2):581-584(2006)Abe, S., et al. Am. J. Hum. Genet. 72(1):73-82(2003)